Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
Even for formulations without B12, avoiding direct light exposure is good practice
The SURMOUNT-2 trial, which investigated tirzepatide for obesity treatment in people with type 2 diabetes, reported a mean body weight reduction of 12.8% and 14.7% for weekly doses of 10 and 15 mg, respectively, after 72 weeks (53)
Body odour, flatulence, increased appetite or rash may occur
A heavy, fatty dinner the night before still has a fair chance of sitting in your stomach when the new dose lands
Ghozland shares that the more evidence you can provide to your insurance provider, the better